-
A New Horizon in Metabolic Health: Understanding Lilly’s Retatrutide
NYSE: $LLY A Breakthrough in Weight Loss and Diabetes Management Eli Lilly and Company has recently unveiled promising clinical trial results for their investigational molecule, retatrutide, a GGG triple hormone receptor agonist. This compound represents a significant leap forward in the treatment of obesity and type 2 diabetes by targeting three distinct pathways simultaneously. Understanding…
-
Biofrontera Announces FDA Approval of Ameluz Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
NASDAQ: $BFRI WOBURN, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today… Source: Read More
-
Clarivate Finalizes Sale of Life Sciences & Healthcare Segment: A New Chapter Begins
NYSE: $CLVT Strategic Realignment for Future Growth Clarivate Plc has officially announced the completion of the sale of its Life Sciences & Healthcare segment. This major divestiture marks a significant milestone in the company’s ongoing strategic transformation, aimed at streamlining operations and sharpening its focus on core business pillars. Key Takeaways from the Transaction By…
-
A New Frontier in Weight Management: AbbVie’s ABBV-295 Shows Promise
NYSE: $ABBV The Quest for Next-Generation Obesity Treatments As the landscape of metabolic medicine continues to evolve, AbbVie has recently stepped into the spotlight with promising new data from its clinical development program. The company has officially shared detailed Phase 1 results for ABBV-295, an experimental, long-acting amylin analog designed to address the complex needs…
-
FDA Approves Reduced Monitoring Time for First Two Doses of Imdelltra
NASDAQ: $AMGN A Significant Update for Small Cell Lung Cancer Treatment The landscape for treating extensive-stage small cell lung cancer (ES-SCLC) is evolving. The FDA has recently approved a label update for Imdelltra (tarlatamab-dlle), specifically changing the requirements for patient monitoring after the administration of the first two doses. What Has Changed? Previously, patients receiving…
-
Kedrion to be Honored at Premier, Inc.’s Annual Supplier Innovation Celebration at the 2026 Breakthroughs Conference and Exhibition
QIVIGY® will be recognized as an innovative healthcare solution advancing care for patients in need of IVIG therapy FORT LEE, N.J., Oct. 6, 2026 /PRNewswire/ — Kedrion Biopharma today announced that it will be honored during Premier’s annual Supplier Innovation Celebration at its 2026… Source: Read More
-
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
NASDAQ: $CGEM CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases… Source: Read More
-
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for Ibtrozi (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
NYSE: $NUVB NEW YORK, Sept. 16, 2026 /PRNewswire/ — Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved… Source: Read More
-
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data for Deramiocel for Upper Limb Function in Duchenne Muscular Dystrophy
NASDAQ: $CAPR SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its… Source: Read More
-
A Breakthrough in Cancer Care: Jaypirca Receives Expanded FDA Approval
NYSE: $LLY A New Chapter for Patients with CLL and SLL The landscape of treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has shifted significantly. Eli Lilly and Company recently announced that the U.S. Food and Drug Administration (FDA) has granted expanded approval for Jaypirca (pirtobrutinib). This milestone marks an important advancement…
-
Advancing Type 1 Diabetes Care: Mozart Therapeutics Shares New Data on MTX-101
A New Frontier in Autoimmune Research At the 62nd EASD Annual Meeting, Mozart Therapeutics took center stage to share critical updates regarding their lead therapeutic candidate, MTX-101. This presentation marks an important milestone for the company as they continue to investigate novel ways to treat autoimmune diseases, specifically focusing on Type 1 Diabetes (T1D). Understanding…
-
Bayer’s Kerendia (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
September 17, 2026 — Bayer today announced that the U.S. Food and Drug Administration (FDA) approved Kerendia® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated… Source: Read More
-
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the… Source: Read More
-
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-Positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
South San Francisco, CA — September 30, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with… Source: Read More
-
A New Chapter for MPS IIIA: FDA Approves Fayuvi (rebisufligene etisparvovec-hopf)
NASDAQ: $RARE A Breakthrough in Genetic Medicine The landscape for treating Sanfilippo syndrome type A (MPS IIIA) has officially changed. The FDA has granted approval for Fayuvi (rebisufligene etisparvovec-hopf), a pioneering gene therapy designed to address the underlying cause of this rare and devastating neurodegenerative condition. Understanding Sanfilippo Syndrome Type A Sanfilippo syndrome type A…
-
CagriSema: The Breakthrough Combo Targeting ‘Food Noise’ and Metabolic Health
A New Frontier in Weight Management Recent clinical updates regarding CagriSema, an investigational drug developed by Novo Nordisk, are generating significant buzz in the medical community. This once-weekly injectable treatment combines semaglutide with cagrilintide, offering a dual-action approach to treating obesity and type 2 diabetes. Silencing ‘Food Noise’ One of the most compelling aspects of…
-
IntraBio Announces U.S. FDA Approval of Aqneursa (levacetylleucine) for Ataxia-Telangiectasia
AUSTIN, Texas–(BUSINESS WIRE) September 18, 2026 –IntraBio Inc., a leader in the discovery, development, and commercialization of novel therapies for rare and common neurodegenerative diseases, today announced that the U.S. Food and Drug… Source: Read More
-
Advancing Women’s Health: AlloSource Launches UroConnex Fascia
A New Standard in Pelvic Reconstructive Surgery AlloSource, a leader in the advancement of regenerative medicine, has officially expanded its portfolio of allografts with the launch of UroConnex Fascia. This innovative product is specifically designed to support surgeons performing complex procedures in the field of women’s health. Understanding UroConnex Fascia UroConnex Fascia is an allograft—tissue…
-
SIBIONICS et PharmaSens explorent de nouvelles perspectives pour l’administration automatisée d’insuline lors du congrès de l’EASD 2026
MILAN, 5 octobre 2026 /PRNewswire/ — Lors du congrès 2026 de l’Association européenne pour l’étude du diabète (EASD), SiBionics a présenté « See More, Act Earlier » (Voir plus : agir plus tôt), qui établit un lien entre la surveillance continue et l’avenir de la prise en charge du… Source: Read More
-
Biogen’s Litifilimab Shows Promise: New Phase 2 Data in Lupus Treatment
NASDAQ: $BIIB A Potential Breakthrough for Lupus Patients Biogen has recently shared encouraging updates regarding litifilimab, an investigational humanized monoclonal antibody currently being studied for the treatment of Systemic Lupus Erythematosus (SLE). New data presented from a 52-week Phase 2 study highlights the drug’s potential to offer both rapid and durable efficacy for those managing…
-
New Hope: FDA Approves Inluriyo (Imlunestrant) Combination for Advanced Breast Cancer
NYSE: $LLY A New Frontier in Targeted Cancer Therapy The landscape of breast cancer treatment has taken a significant step forward with the recent FDA approval of Inluriyo (imlunestrant). This novel medication, used in combination with Verzenio (abemaciclib), offers a new targeted approach for specific patient populations battling advanced or metastatic breast cancer. Understanding the…
-
A New Milestone in Blood Cancer Treatment: FDA Expands Approval for Jaypirca
NYSE: $LLY A New Therapeutic Option for CLL/SLL Patients The landscape of blood cancer treatment has taken a significant step forward. The U.S. Food and Drug Administration (FDA) has granted expanded approval for Jaypirca (pirtobrutinib), marking it as the first and only non-covalent BTK inhibitor available for patients with previously untreated chronic lymphocytic leukemia (CLL)…
-
Pfizer’s Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
NYSE: $PFE NEW YORK–(BUSINESS WIRE) October 01, 2026 — Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its… Source: Read More
-
FDA Approves Bravnetsa (lutetium Lu 177 dotatate) as a Therapeutic Equivalent to Lutathera for the Treatment of Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors in Adults
NASDAQ: $LNTH BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver… Source: Read More